HRP20181454T1 - Modificirani krvni čimbenici s niskim stupnjem sadržaja u vodi topljivog polimera - Google Patents

Modificirani krvni čimbenici s niskim stupnjem sadržaja u vodi topljivog polimera

Info

Publication number
HRP20181454T1
HRP20181454T1 HRP20181454TT HRP20181454T HRP20181454T1 HR P20181454 T1 HRP20181454 T1 HR P20181454T1 HR P20181454T T HRP20181454T T HR P20181454TT HR P20181454 T HRP20181454 T HR P20181454T HR P20181454 T1 HRP20181454 T1 HR P20181454T1
Authority
HR
Croatia
Prior art keywords
water
soluble polymer
low content
blood factors
modified blood
Prior art date
Application number
HRP20181454TT
Other languages
English (en)
Croatian (hr)
Inventor
Peter Turecek
Juergen Siekmann
Hanspeter Rottensteiner
Original Assignee
Baxalta GmbH
Baxalta Incorporated
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxalta GmbH, Baxalta Incorporated filed Critical Baxalta GmbH
Publication of HRP20181454T1 publication Critical patent/HRP20181454T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21021—Coagulation factor VIIa (3.4.21.21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21022—Coagulation factor IXa (3.4.21.22)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
HRP20181454TT 2008-10-17 2009-10-16 Modificirani krvni čimbenici s niskim stupnjem sadržaja u vodi topljivog polimera HRP20181454T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10642408P 2008-10-17 2008-10-17
PCT/US2009/061023 WO2010045568A1 (en) 2008-10-17 2009-10-16 Modified blood factors comprising a low degree of water soluble polymer
EP09752930.9A EP2349342B1 (en) 2008-10-17 2009-10-16 Modified blood factors comprising a low degree of water soluble polymer

Publications (1)

Publication Number Publication Date
HRP20181454T1 true HRP20181454T1 (hr) 2018-12-14

Family

ID=41650072

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20181454TT HRP20181454T1 (hr) 2008-10-17 2009-10-16 Modificirani krvni čimbenici s niskim stupnjem sadržaja u vodi topljivog polimera

Country Status (20)

Country Link
US (4) US20100099616A1 (enExample)
EP (3) EP3437661A1 (enExample)
JP (2) JP5785872B2 (enExample)
KR (2) KR20110071012A (enExample)
AU (1) AU2009305612B2 (enExample)
BR (1) BRPI0920259A8 (enExample)
CA (1) CA2738679A1 (enExample)
CY (1) CY1120921T1 (enExample)
DK (1) DK2349342T3 (enExample)
ES (1) ES2692172T3 (enExample)
HR (1) HRP20181454T1 (enExample)
HU (1) HUE039906T2 (enExample)
LT (1) LT2349342T (enExample)
MX (1) MX2011004085A (enExample)
NZ (1) NZ592688A (enExample)
PL (1) PL2349342T3 (enExample)
PT (1) PT2349342T (enExample)
SI (1) SI2349342T1 (enExample)
SM (1) SMT201800486T1 (enExample)
WO (1) WO2010045568A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2744370C2 (ru) 2009-07-27 2021-03-05 Баксалта Инкорпорейтед Конъюгаты белков свертывания крови
EP2536753B1 (en) 2010-02-16 2017-12-20 Novo Nordisk A/S Factor viii molecules with reduced vwf binding
GB201007356D0 (en) 2010-04-30 2010-06-16 Leverton Licence Holdings Ltd Conjugated factor VIIa
JP2013532176A (ja) * 2010-07-15 2013-08-15 ノヴォ ノルディスク アー／エス 安定化させた第ｖｉｉｉ因子バリアント
MX354705B (es) 2011-09-23 2018-03-16 Novo Nordisk As Analogos de glucagon novedosos.
HK1200695A1 (en) * 2012-04-16 2015-08-14 Cantab Biopharmaceuticals Patents Limited Optimised subcutaneous therapeutic agents
BR112015025464A2 (pt) 2013-04-18 2017-10-10 Novo Nordisk As coagonistas do receptor de glp-1/glucagon estáveis, prolongados para uso médico
JP2017525656A (ja) 2014-06-04 2017-09-07 ノヴォ ノルディスク アー／エス 医療用のｇｌｐ−１／グルカゴン受容体コアゴニスト
JP6516829B2 (ja) 2014-08-04 2019-05-22 シーエスエル、リミテッド 第ｖｉｉｉ因子製剤
SG11201706659WA (en) 2015-03-06 2017-09-28 Csl Behring Recombinant Facility Ag Modified von willebrand factor having improved half-life
JP6552286B2 (ja) * 2015-06-05 2019-07-31 公立大学法人奈良県立医科大学 凝固第ｖｉｉｉ因子の複合体形成能に関する情報の取得方法および試薬キット
WO2021001522A1 (en) 2019-07-04 2021-01-07 CSL Behring Lengnau AG A truncated von willebrand factor (vwf) for increasing the in vitro stability of coagulation factor viii
WO2021094344A1 (en) 2019-11-11 2021-05-20 CSL Behring Lengnau AG Polypeptides for inducing tolerance to factor viii

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4757006A (en) 1983-10-28 1988-07-12 Genetics Institute, Inc. Human factor VIII:C gene and recombinant methods for production
US4970300A (en) * 1985-02-01 1990-11-13 New York University Modified factor VIII
US6048729A (en) 1987-05-01 2000-04-11 Transkaryotic Therapies, Inc. In vivo protein production and delivery system for gene therapy
US5122614A (en) * 1989-04-19 1992-06-16 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
US5252714A (en) 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
US6063630A (en) * 1991-11-05 2000-05-16 Transkaryotic Therapies, Inc. Targeted introduction of DNA into primary or secondary cells and their use for gene therapy
US6037452A (en) * 1992-04-10 2000-03-14 Alpha Therapeutic Corporation Poly(alkylene oxide)-Factor VIII or Factor IX conjugate
US5298643A (en) * 1992-12-22 1994-03-29 Enzon, Inc. Aryl imidate activated polyalkylene oxides
WO1994015625A1 (en) 1993-01-15 1994-07-21 Enzon, Inc. Factor viii - polymeric conjugates
US5621039A (en) * 1993-06-08 1997-04-15 Hallahan; Terrence W. Factor IX- polymeric conjugates
US5824784A (en) * 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US6238908B1 (en) 1995-06-07 2001-05-29 Aastrom Biosciences, Inc. Apparatus and method for maintaining and growth biological cells
US7074878B1 (en) 1999-12-10 2006-07-11 Harris J Milton Hydrolytically degradable polymers and hydrogels made therefrom
US20030211094A1 (en) * 2001-06-26 2003-11-13 Nelsestuen Gary L. High molecular weight derivatives of vitamin k-dependent polypeptides
ES2363205T3 (es) * 2002-06-21 2011-07-26 Novo Nordisk Health Care Ag Glicoformas del factor vii pegilado.
WO2004056852A2 (en) 2002-12-19 2004-07-08 Nektar Therapeutics Al, Corp. Cyanovirin variant-polymer conjugates
EP1596887B1 (en) * 2003-02-26 2022-03-23 Nektar Therapeutics Polymer-factor viii moiety conjugates
AU2004221824B2 (en) * 2003-03-14 2009-08-27 Ratiopharm Gmbh Branched water-soluble polymers and their conjugates
JP2008505119A (ja) * 2004-06-30 2008-02-21 ネクター セラピューティクス アラバマ，コーポレイション 高分子−第ｉｘ因子部分の抱合体
DK2371856T3 (en) * 2004-11-12 2022-08-08 Bayer Healthcare Llc Site-directed modifikation af FVIII
AU2005322067B8 (en) * 2004-12-27 2012-07-26 Takeda Pharmaceutical Company Limited Polymer-von Willebrand factor-conjugates
WO2006114105A2 (en) * 2005-04-26 2006-11-02 Maxygen Holdings Ltd. Use of modified factor vii for treating bleeding
US20080255026A1 (en) * 2005-05-25 2008-10-16 Glycopegylated Factor 1X Glycopegylated Factor Ix
WO2007126808A1 (en) 2006-03-31 2007-11-08 Baxter International Inc Pegylated factor viii
US7645860B2 (en) * 2006-03-31 2010-01-12 Baxter Healthcare S.A. Factor VIII polymer conjugates
DK2101821T3 (da) * 2006-12-15 2014-10-06 Baxter Healthcare Sa Faktor VIIA-(poly)sialinsyre-konjugat med forlænget halveringstid in vivo
MX2009007145A (es) * 2006-12-27 2009-08-27 Nektar Therapeutics Al Corp Conjugados de polimero con factor viii y factor de von willebrand que tienen una ligadura liberable.

Also Published As

Publication number Publication date
HUE039906T2 (hu) 2019-02-28
ES2692172T3 (es) 2018-11-30
US20100099616A1 (en) 2010-04-22
MX2011004085A (es) 2011-09-27
EP3620177A1 (en) 2020-03-11
JP2015110676A (ja) 2015-06-18
EP2349342B1 (en) 2018-06-27
US20190160178A1 (en) 2019-05-30
BRPI0920259A2 (pt) 2016-01-05
AU2009305612B2 (en) 2015-05-21
KR20160103173A (ko) 2016-08-31
SMT201800486T1 (it) 2018-11-09
EP2349342A1 (en) 2011-08-03
KR20110071012A (ko) 2011-06-27
EP3437661A1 (en) 2019-02-06
US20120076749A1 (en) 2012-03-29
US20160199503A1 (en) 2016-07-14
PT2349342T (pt) 2018-10-26
BRPI0920259A8 (pt) 2017-09-19
AU2009305612A1 (en) 2010-04-22
WO2010045568A1 (en) 2010-04-22
JP2012505917A (ja) 2012-03-08
DK2349342T3 (en) 2018-10-08
CA2738679A1 (en) 2010-04-22
JP5785872B2 (ja) 2015-09-30
CY1120921T1 (el) 2019-12-11
NZ592688A (en) 2012-12-21
PL2349342T3 (pl) 2019-01-31
KR101929641B1 (ko) 2018-12-14
SI2349342T1 (sl) 2018-10-30
LT2349342T (lt) 2018-10-10

Similar Documents

Publication Publication Date Title
HUE039906T2 (hu) Alacsony fokú vízben oldható polimer tartalmú módosított vérfaktorok
BRPI0921822A2 (pt) composição compreendendo polímero e enzima
EP2440221A4 (en) COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF ERYTHROCYTE GERMINS
EP2351365A4 (en) MULTIPLE coding CONTENT SUBSTITUTION
PL2461700T3 (pl) Środek konserwujący do wody i pożywienia
EP2635185A4 (en) DETERMINATION OF OXYGENATION OF IN VIVO TISSUE
HUE046780T2 (hu) Kannabidiol használata aripiprazollal kombinálva
EP2249895A4 (en) PLATINUM COBALT BOR BLOOD PUMPING ELEMENT
IL212471A (en) Composition of tissue or fat cells and polyoxomer p188 for use in tissue or fat cell transplantation
EP2310039A4 (en) FGF-9 AND ITS APPLICATION IN CONNECTION WITH BLOOD VESSELS
BRPI0922989A2 (pt) Liberação sustentada de nutrientes in vivo
ZA201305498B (en) Methods and compositions suitable for managing blood glucose in animals
UY33079A (es) Derivados de difenil -pirazolopiridinas, su preparación y su aplicación en terapeutica
GB0705187D0 (en) Improvements in or relating to level measurement
PL2358413T3 (pl) Pulsacyjne urządzenie medyczne przeznaczone do stosowania w chirurgii pozaustrojowej
EP2515915A4 (en) COMPOSITIONS AND METHODS RELATING TO MIRNA IN DIABETIC DRESSES
EP2275940A4 (en) CONTENTS DISPLAY
BRPI0921791A2 (pt) Composições de polímeros de dihidroxiacetona e usos das mesmas
GB0822283D0 (en) Improvements in or relating to level sensors
PL2291657T3 (pl) Stężenie heterotrimerów blys/april w surowicy oraz zastosowanie w sposobach diagnostycznych
IL207647A0 (en) Use of interleukin-1 conjugates in the treatment of diabetes
BRPI0821700A2 (pt) Métodos para determinar o número de moléculas de polímero fisiologicamente aceitáveis ligadas a uma proteína ou a um complexo de proteína em um conjugado polímero-proteína e para determinar o número de moléculas de polímero fisiologicamente aceitáveis ligadas a uma proteína ou a um complexo de proteína ou livre em solução
BRPI0914785A2 (pt) preparação farmacêutica em recipientes permeáveis ao vapor de água com estabilidade aperfeiçoada
DK2250179T3 (da) Lecithin-baseret sammensætning og dens anvendelse i fødevarer
EP2455090A4 (en) MEANS TO INHIBIT THE INCREASE OF THE POSTPRANDIAL BLOOD INSULIN MIRROR